Compare EPAM Systems Inc (EPAM) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

EPAM Systems trades at $113.54, up 4.82% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $119 suggest upside potential. The company reported $5.46B in 2025 revenue, with a net income margin of 7.15%, while maintaining solid cash flow from operations of $654.93M.

The outlook is positive, driven by AI-native revenue growth exceeding 11% and activist shareholder pressure for buybacks. Risks include slower North American growth and competitive pressures in digital transformation services. The stock's current valuation at a P/E of 15.45 appears reasonable relative to earnings growth prospects.

Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.

The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.